BioAtla, Inc. (BCAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
BCAB Stock Price Chart Interactive Chart >
BCAB Price/Volume Stats
|Current price||$10.41||52-week high||$25.43|
|Prev. close||$9.85||52-week low||$2.01|
|Day high||$10.50||Avg. volume||766,104|
|50-day MA||$7.88||Dividend yield||N/A|
|200-day MA||$5.64||Market Cap||391.49M|
BioAtla, Inc. (BCAB) Company Bio
BioAtla LLC develops conditionally active biologic antibody therapeutics. The firm's technologies include conditionally active biologics, comprehensive integrated antibody optimization, CPE and CPS, gigamab, and versitop. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Most Popular Stories View All
BCAB Latest News Stream
|Loading, please wait...|
BCAB Latest Social Stream
View Full BCAB Social Stream
Latest BCAB News From Around the Web
Below are the latest news stories about BIOATLA INC that investors may wish to consider to help them evaluate BCAB as an investment opportunity.
The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Scott Smith, President and Sheri Lydick, Senior Vice President, Commercial Strategy will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 1
We're starting off the final day of trading this week with a look at the biggest pre-market stock movers for Friday morning!
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BCAB Price Returns